Cargando…

Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study

Autism spectrum disorder (ASD) is a pervasive neurodevelopmental disorder with repetitive behaviour which affects interaction and communication. Sulforaphane (SFN), an isothiocyanate abundant in the seeds and sprouts of cruciferous vegetables, has been shown to be effective in alleviating autistic b...

Descripción completa

Detalles Bibliográficos
Autores principales: Magner, Martin, Thorová, Kateřina, Župová, Veronika, Houška, Milan, Švandová, Ivana, Novotná, Pavla, Tříska, Jan, Vrchotová, Naděžda, Soural, Ivo, Jílek, Ladislav
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9920098/
https://www.ncbi.nlm.nih.gov/pubmed/36771424
http://dx.doi.org/10.3390/nu15030718
_version_ 1784886987061198848
author Magner, Martin
Thorová, Kateřina
Župová, Veronika
Houška, Milan
Švandová, Ivana
Novotná, Pavla
Tříska, Jan
Vrchotová, Naděžda
Soural, Ivo
Jílek, Ladislav
author_facet Magner, Martin
Thorová, Kateřina
Župová, Veronika
Houška, Milan
Švandová, Ivana
Novotná, Pavla
Tříska, Jan
Vrchotová, Naděžda
Soural, Ivo
Jílek, Ladislav
author_sort Magner, Martin
collection PubMed
description Autism spectrum disorder (ASD) is a pervasive neurodevelopmental disorder with repetitive behaviour which affects interaction and communication. Sulforaphane (SFN), an isothiocyanate abundant in the seeds and sprouts of cruciferous vegetables, has been shown to be effective in alleviating autistic behaviour. We performed a prospective double-blind placebo-controlled study to examine the possible effect of SFN in a paediatric cohort aged three to seven years based on measurements of the Autism Diagnostic Observation Schedule-2 (ADOS-2), the Social Responsiveness Scale-2 (SRS-2), and the Aberrant Behaviour Checklist (ABC). The study consisted of three visits over the duration of 36 weeks (baseline, 18 weeks, and 36 weeks). Twenty-eight of the 40 randomized children completed the study. The mean total raw scores on ABC and SRS-2 improved in both groups, but none of the changes reached statistical significance (ABC: 0 weeks p = 0.2742, 18 weeks p = 0.4352, and 36 weeks 0.576; SRS-2: 0 weeks p = 0.5235, 18 weeks p = 0.9176, and 36 weeks 0.7435). Changes in the assessment of the ADOS-2 subscale scores also did not differ between the two study cohorts (ADOS-2: 0 weeks p = 0.8782, 18 weeks p = 0.4788, and 36 weeks 0.9414). We found no significant clinical improvement in the behavioural outcome measures evaluated in children with ASD aged 3–7 years that were treated with sulforaphane.
format Online
Article
Text
id pubmed-9920098
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99200982023-02-12 Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study Magner, Martin Thorová, Kateřina Župová, Veronika Houška, Milan Švandová, Ivana Novotná, Pavla Tříska, Jan Vrchotová, Naděžda Soural, Ivo Jílek, Ladislav Nutrients Article Autism spectrum disorder (ASD) is a pervasive neurodevelopmental disorder with repetitive behaviour which affects interaction and communication. Sulforaphane (SFN), an isothiocyanate abundant in the seeds and sprouts of cruciferous vegetables, has been shown to be effective in alleviating autistic behaviour. We performed a prospective double-blind placebo-controlled study to examine the possible effect of SFN in a paediatric cohort aged three to seven years based on measurements of the Autism Diagnostic Observation Schedule-2 (ADOS-2), the Social Responsiveness Scale-2 (SRS-2), and the Aberrant Behaviour Checklist (ABC). The study consisted of three visits over the duration of 36 weeks (baseline, 18 weeks, and 36 weeks). Twenty-eight of the 40 randomized children completed the study. The mean total raw scores on ABC and SRS-2 improved in both groups, but none of the changes reached statistical significance (ABC: 0 weeks p = 0.2742, 18 weeks p = 0.4352, and 36 weeks 0.576; SRS-2: 0 weeks p = 0.5235, 18 weeks p = 0.9176, and 36 weeks 0.7435). Changes in the assessment of the ADOS-2 subscale scores also did not differ between the two study cohorts (ADOS-2: 0 weeks p = 0.8782, 18 weeks p = 0.4788, and 36 weeks 0.9414). We found no significant clinical improvement in the behavioural outcome measures evaluated in children with ASD aged 3–7 years that were treated with sulforaphane. MDPI 2023-01-31 /pmc/articles/PMC9920098/ /pubmed/36771424 http://dx.doi.org/10.3390/nu15030718 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Magner, Martin
Thorová, Kateřina
Župová, Veronika
Houška, Milan
Švandová, Ivana
Novotná, Pavla
Tříska, Jan
Vrchotová, Naděžda
Soural, Ivo
Jílek, Ladislav
Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study
title Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study
title_full Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study
title_fullStr Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study
title_full_unstemmed Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study
title_short Sulforaphane Treatment in Children with Autism: A Prospective Randomized Double-Blind Study
title_sort sulforaphane treatment in children with autism: a prospective randomized double-blind study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9920098/
https://www.ncbi.nlm.nih.gov/pubmed/36771424
http://dx.doi.org/10.3390/nu15030718
work_keys_str_mv AT magnermartin sulforaphanetreatmentinchildrenwithautismaprospectiverandomizeddoubleblindstudy
AT thorovakaterina sulforaphanetreatmentinchildrenwithautismaprospectiverandomizeddoubleblindstudy
AT zupovaveronika sulforaphanetreatmentinchildrenwithautismaprospectiverandomizeddoubleblindstudy
AT houskamilan sulforaphanetreatmentinchildrenwithautismaprospectiverandomizeddoubleblindstudy
AT svandovaivana sulforaphanetreatmentinchildrenwithautismaprospectiverandomizeddoubleblindstudy
AT novotnapavla sulforaphanetreatmentinchildrenwithautismaprospectiverandomizeddoubleblindstudy
AT triskajan sulforaphanetreatmentinchildrenwithautismaprospectiverandomizeddoubleblindstudy
AT vrchotovanadezda sulforaphanetreatmentinchildrenwithautismaprospectiverandomizeddoubleblindstudy
AT souralivo sulforaphanetreatmentinchildrenwithautismaprospectiverandomizeddoubleblindstudy
AT jilekladislav sulforaphanetreatmentinchildrenwithautismaprospectiverandomizeddoubleblindstudy